Table 5.

Cumulative percentage in patients in the BPaMZ group with rifampicin-resistant tuberculosis and culture negative overnight sputum samples, and the median time to sputum culture conversion

	Pyrazinamide-susceptible rifampicin-resistant tuberculosis (n=38)	Pyrazinamide-resistant	rifampicin-resistant tuberculosis (n=22)
Percentage culture negative at day 56 of treatment (95% CI)
	Liquid culture	96·0% (88·5–100·0)	79·8% (62·4–97·2)
	Solid culture	100·0% (100·0–100·0)	95·0% (85·3–100·0)
Liquid culture median (IQR) time to culture negative, days		41 (35–56)	49 (34–56)

BPaMZ=bedaquiline (daily dose), pretomanid, and pyrazinamide plus moxifloxacin.